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Little is known about the functional differences
between the human skin myeloid dendritic cell (DC)
subsets, epidermal CD207+ Langerhans cells (LCs)
and dermal CD14+ DCs. We showed that CD14+
DCs primed CD4+ T cells into cells that induce naive
B cells to switch isotype and become plasma cells. In
contrast, LCs preferentially induced the differentia-
tion of CD4+ T cells secreting T helper 2 (Th2) cell
cytokines and were efficient at priming and cross-
priming naive CD8+ T cells. A third DC population,
CD14CD207CD1a+ DC, which resides in the der-
mis, could activate CD8+ T cells better than CD14+
DCs but less efficiently than LCs. Thus, the human
skin displays three DC subsets, two of which, i.e.,
CD14+ DCs and LCs, display functional specializa-
tions, the preferential activation of humoral and
cellular immunity, respectively.
INTRODUCTION
Pioneering studies in the late 19th and early 20th centuries led to
the understanding that the immune system has two primary
effector modalities: a cellular arm whose function was first de-
scribed in Metchnikoff’s studies of phagocytes and a humoral
arm whose properties were detailed by the work of Behring,
Kitasato, and Ehrlich on antitoxins (Silverstein, 2003). Decades
of debate between the ‘‘humoralists’’ and ‘‘cellularists’’ about
the basis of immune protection eventually led to the present
view that both arms are critical for vertebrates’ survival. B cells
and CD8+ T cells are the primary effectors of the adaptive im-
mune system, whereas CD4+ T cells both regulate the functions
of these other lymphocyte types and have effector activities of
their own (Germain, 2004). Each of these cell types is composed
of subsets with specialized functions. The CD4+ T cell compart-
ment is particularly complex because it includes T helper (Th) 1,
Th2, Th17 (Weaver et al., 2007), and follicular helper T (Tfh) cells
(King et al., 2008) that arise by polarized differentiation of naive
precursors, as well as regulatory T (Treg) cells (Sakaguchi
et al., 2006; Shevach, 2006).T cells are under the control of dendritic cells (DCs), which
stimulate immunologically naive T cells after the efficient forma-
tion and presentation of specific peptide-MHC complexes
(Banchereau and Steinman, 1998; Steinman and Banchereau,
2007). More than that, DCs control the ‘‘polarization’’ of T cell re-
sponses by delivering a variety of signals that differentially skew
effector T cell development. DCs also play a critical role main-
taining peripheral tolerance by downregulating T cell responses
to self-antigens. The ability of DCs to induce specific types of
T cell responses reflects the type of maturation signals they re-
ceive at the time of antigen encounter. In addition, it is becoming
clear that distinct DC subsets exist, and such subsets have been
associated with specific T cell outcomes in addition to the stim-
ulation of B cell and NK cell responses. Two major DC subtypes
are recognized: the myeloid DCs (mDCs) and the plasmacytoid
DCs (pDCs) (Banchereau et al., 2000; Shortman and Liu, 2002).
Inmice, splenicmDCswere originally shown to be composedof
twomajormDCsubsetswithmarkeddifferences inbiological func-
tion: CD8a+CD11b ‘‘lymphoid’’ DCs and CD8aCD11b+ ‘‘mye-
loid’’ DCs. CD8a+ DCs are able to produce large amounts of
IL-12 and polarize naive CD4+ T cells toward the Th1 cell pheno-
type, whereas CD8a DCs preferentially induce Th2 cell
responses (Maldonado-Lopez et al., 1999; Pulendran et al., 1999;
Soares et al., 2007). Acquiring a better understanding of the role of
mDC subsets in the activation of distinct arms of the adaptive im-
mune system is critical to the generation of new vaccines that ad-
dress chronic diseases, such as HIV-mediated AIDS, malaria, or
Hepatitis C, for which no vaccines are available (Pulendran and
Ahmed, 2006). Although the study of mouse DC subsets can
make important contributions in this regard, it is crucial to do such
studies with human cells because major differences exist between
the human and mouse immune systems (Mestas and Hughes,
2004). Thus, to successfully generate human vaccines, we need
to understand the diversity and biology of human DC subsets.
In human skin, at least two different mDC subsets have been
characterized: epidermal Langerhans cells (LCs) and dermal in-
terstitial DCs (dermal DCs) (Nestle et al., 1993; Valladeau and
Saeland, 2005). Over the years, dermal DCs were further subdi-
vided into at least two subsets. The presence of two dermal DC
subsets was also recently reported in mice that display a Lan-
gerin (CD207) subset in the dermis (Bursch et al., 2007; Ginhoux
et al., 2007; Poulin et al., 2007). Detailed functional studies of
these different mDC populations have progressed slowly, mostlyImmunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 497
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tissues. However, such studies were in part feasible when we
found that culturing CD34+ hematopoietic progenitor cells
(CD34-HPC) with GM-CSF and TNF-a gives rise to both
CD1a+CD14 LCs, and CD14+CD1a DCs. CD14+ DCs were
found to be unique in their ability to induce the differentiation of
naive B cells into IgM-secreting plasma cells (Caux et al., 1997).
No unique functions could, however, be identified for LCs. Here,
we report our detailed study of the biological functions of two of
the threeDC subsets of human skin, LCs and dermal CD14+DCs.
RESULTS
Generation and Isolation of Human mDC Subsets
We have analyzed the biological functions of human mDC sub-
sets that are either isolated from epidermis and dermis or gener-
ated in vitro by culturing blood CD34+ HPCs with GM-CSF,
Flt3-L, and TNF-a. In brief, a dispase treatment of skin samples
enabled us to separate the epidermis from the dermis, and cells
were allowed to migrate for two days before purification with cell
sorting. Epidermal sheets yielded CD1ahiCD14HLA-DR+ cells
expressing Langerin (CD207), a marker of LCs (Figure 1A). Der-
mis yielded two distinct populations: CD1aCD14+HLA-DR+
cells (dermal CD14+ DCs) and CD1adimCD14HLA-DR+ cells
(dermal CD1a+ DCs) (Figure 1A). Studies performed with twelve
skin samples revealed that LCs represented 58% of all the DCs
that were isolated, whereas dermal CD1a+ DCs CD14+ DCs rep-
resent respectively 30% and 12% of all isolated DCs (Figure S1A
available online). In situ analysis showed that dermal CD1a+ DCs
were mostly located in the upper dermis (Figure S1B).
DCs generated in vitro by culturing CD34+ HPCs for 9 days
were sorted into CD1a+CD14 LCs (LCs) and CD1aCD14+
DCs (CD14+ DCs) (Figure 1B). Both skin LCs and in vitro-gener-
ated LCs expressed Langerin (CD207) and high amounts of
costimulatory molecules (CD80, CD86, and CD40, Figure 1C).
The three skin DC populations expressed CD11c. Neither of the
two dermal DC populations expressed Langerin (CD207)
(Figure1CandFiguresS1CandS1D), in contrast to the recentde-
scription of mouse Langerin (CD207)+ dermal DCs. CD14+ DCs
uniquely expressed DC-SIGN, as well as CD163 and transcribed
factor XIIIa (Figures S1E and S1F), but did not express CD1c. The
two other CD1a+ DC populations expressed CD1c (Figure 1C).
Upon stimulation through CD40, different cytokines were
secreted by the different DCs. CD14+ DCs secreted IL-10,
MCP-1, IL-1b, IL-6, TNF-a, and GM-CSF (Figure 1D) and tran-
scribed TGF-b and IL-10 (Figures S2A andS2B), whereas epider-
mal LCs and dermal CD1a+ DCs did not. In contrast, epidermal
LCs and dermal CD1a+ DCs transcribed (Figure S2C) and se-Icreted IL-15 (Figure 1D). The two dermal DC subsets secreted
large amounts of IL-8, whereas LCs secreted much less.
In vitro-generated CD14+ DCs produced the same cytokines as
skin dermal CD14+ DCs (de Saint-Vis et al., 1998). IL-15 was pro-
duced by in vitro-generated LCs (Figure S2D). Thus, LCs and
CD14+DCsgenerated invitroshowedaphenotype remarkablysim-
ilar to that of LCs and CD14+ DCs isolated from skin, respectively.
LCs Prime CD4+ T Cells to Secrete Th2
Cell-Type Cytokines
A function unique to DCs is their capacity to induce allogeneic
naive CD4+ T cells to proliferate (mixed lymphocyte reaction
[MLR]). Indeed, LCs from skin were powerful stimulators of naive
CD4+ T cell proliferation (Figure 2A), whereas dermal CD14+ DCs
were weaker. Dermal CD1a+ DCs showed intermediate activity.
In vitro-generated LCs were also strong stimulators of naive
CD4+ T cell proliferation (Figure 2B and Figure S3). In contrast,
in vitro-generated CD14+ DCs were weaker stimulators, and
MLR performed with LCs yielded higher numbers of CD4+
T cells than that performed with CD14+ DCs (Figure S3).
We cocultured the purified skin DC subsets for 7 days with
allogeneic naive CD4+ T cells to examine their capacity to polar-
ize cytokine secretion. Activated CD4+ T cells were restimulated
overnight with CD3 and CD28 microbeads. The three skin DC
subsets induced CD4+ T cells that produced comparable
amounts of IL-2 and IFN-g (Figure 2C). However, LCs were re-
markably efficient at inducing CD4+ T cells to secrete Th2 cell-
type cytokines (IL-4, IL-5, and IL-13). Dermal CD1a+ DCs primed
CD4+T cells to secrete less IL-5 and IL-13when compared to LC-
primed CD4+ T cells but more than those primed by CD14+ DCs.
No IL-4 was detected by CD4+ T cells primed by dermal CD1a+
DCs. The in vitro-generated mDC subsets behaved like their
in vivo counterparts, with LCs being more efficient inducers of
Th2 cell-type cytokine secretion by CD4+ T cells compared to
CD14+ DCs (Figure 2D). Both mDC subsets induced the genera-
tion of IFN-g- and IL-4-producing polarizedCD4+ T cells. Two cy-
cles of T cell stimulation with the same DC subset yielded amore
profound skewing of T cell differentiation by LCs toward Th2 cells
(Figure 2E). The differential ability of the DC subsets to trigger
CD4+ T cell proliferation and polarization was upheld upon mat-
uration with either LPS or CD40L (Figure S4). Thus, LCs are
more efficient than CD14+ DCs in inducing the polarization of
naive CD4+ T cells into Th2 cell-type cytokine-secreting cells.
CD14+ DCs Polarize Naive CD4+ T Cells
into Follicular Helper T Cells
Th2 cells induce mouse naive B cells to switch toward IgG1 and
IgE in an IL-4-dependent manner, whereas Th1 cells induce anFigure 1. Purification and Characterization of Epidermal and Dermal DCs Obtained from Human Skin and of In Vitro CD34+-HPC-Derived
mDC Subsets
(A) Epidermal- and dermal-resident DCs were allowed to migrate from their respective tissues and were harvested after 2 days. The cells were enriched with
a Ficoll-diatrizoate gradient, stained with CD1a and CD14 mAbs, and analyzed by flow cytometry. Epidermal sheets yielded CD1ahiCD14 cells (LCs). Dermis
yielded two distinct populations: CD1aCD14+ cells (dermal CD14+ DCs) and CD1adimCD14 cells (dermal CD1a+ DCs).
(B) CD34+-HPCs cultured with GM-CSF and TNF-a for 9 days were stained with CD1a and CD14 mAbs so that we could identify two subpopulations of mDCs:
CD1a+ LCs and CD14+ DCs.
(C) Flow-cytometry analysis of isolated epidermal and dermal cells or in vitro-generated CD34-derived DC subsets. Cells were gated on CD1a+ or CD14+
populations and analyzed for the expression of Langerin, DC-SIGN, CD80, CD86, CD163, CD1c, CD11c, HLA-DR, E-cadherin, and CD40.
(D) IL-15, IL-10, IL-6, IL-8, MCP-1, IL-12p40, IL-1b, GM-CSF, and TNF-a were measured by a multiplex bead assay in the culture supernatant of sorted LCs,
dermal CD1a+ DCs, and dermal CD14+ DCs after activation with CD40L for 24 hr. Data are representative of three independent experiments.mmunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 499
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that Secrete Th2 Cell-Type Cytokines
(A) Proliferation of allogeneic naive CD4+ T cells, primed with sorted skin LCs, dermal CD1a+ DCs, or dermal CD14+ DCs, was measured after 5 days by [H3]-
thymidine incorporation. The graph shows means ± SD, n = 3. Data are representative of four independent experiments.
(B) Proliferation of allogeneic naive CD4+ T cells, primed by sorted in vitro-generated LCs or CD14+ DCs, wasmeasured after 5 days by the level of [H3]-thymidine
incorporation. The graph shows means ± SD, n = 3. Data are representative of five independent experiments.
(C) Proliferating naive CD4+ T cells, primed by skin mDC subsets, were sorted and restimulated with CD3 and CD28 mAbs overnight. IL-2, IL-4, IL-5, IL-10, IL-13,
IFN-g, and TNF-a were analyzed by a multiplex bead assay (Luminex). The graph shows means ± SD, n = 3. Data are representative of three independent
experiments.
(D) Proliferating naive CD4+ T cells, primed by in vitro-generatedmDC subsets, were sorted and restimulated with CD3 andCD28mAbs overnight. IL-2, IL-4, IL-5,
IL-10, IL-13, IFN-g, and TNF-a were analyzed by a multiplex bead assay (Luminex). Data are representative of five independent experiments.
(E) Naive CD4+ T cells cultured for 6 days with each in vitro-generated mDC subset were stimulated with PMA and ionomycin in the presence of monensin. Intra-
cytoplasmic cytokines were analyzed by flow cytometry with anti-IFN-g and anti-IL-4 (upper panel). Some CD4+ T cells were restimulated with the same DC
subset for 3 days before the cytokine analysis (lower panel). Data are representative of ten independent experiments.500 Immunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc.
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(A) Naive B cells were cultured with the indicated number of CD4+ T cells, which were primed for 7 days prior by distinct skin mDC subsets (left panel) or in vitro-
generated mDC subsets (right panel). IgM, IgG, and IgA production was analyzed on day 14 of the coculture by ELISA. The graph shows means ± SD, n = 3.
(B) CD4+ T cells that were primed by skin mDC subsets (day 7) were restimulated overnight with CD3 and CD28 mAbs, and the production of CXCL13 was mea-
sured by ELISA. Data are representative of two independent experiments.
(C) CD4+ T cells that were primed by in vitro-generated mDC subsets (day 7) were restimulated overnight with CD3 and CD28 mAbs, and the production of
CXCL13 was measured by ELISA. The graph shows means ± SD, n = 5.IFN-g-dependent switch toward IgG2a. It is currently thought
that these T cells are involved in the extrafollicular pathway of
B cell differentiation to induce short-lived plasma cells outside
the germinal center. Another subset of CD4+ T cells, Tfh cells,
promotes the differentiation of B cells into high-affinity anti-
body-secreting cells within germinal centers (King et al., 2008).
Thus, allogeneic naive CD4+ T cells, cultured for one week with
the three purified skin DC subsets, were tested for their ability
to activate naive B cells. Activated CD4+ T cells were sorted
free of DCs at day 7 and cultured for 14 days with naive IgM+IgD+IB cells preactivated with CpG2006 (a TLR-9 ligand) and IgM
mAb. CD4+ T cells cultured with dermal CD14+ DCs induced na-
ive B cells to produce large amounts of IgM (Figure 3A, left
panel). CD4+ T cells cultured with LCs or dermal CD1a+ DCs
can also induce naive B cells to secrete IgMbut to a lower extent.
However, CD4+ T cells cultured with dermal CD14+ DCs induce
naive B cells to switch isotype secretion toward IgG and IgA. In
contrast, CD4+ T cells cultured with LCs did not induce naive B
cells to switch isotypes. The dermal CD1a+ DCs were slightly
more efficient than the LCs but much less than the dermalmmunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 501
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ated CD14+ DCs, but not in vitro-generated LCs, were also able
to induce the differentiation of naive CD4+ T cells into cells that
could induce naive B cells to switch isotype (Figure 3A, right
panel). Consistent with a Tfh cell phenotype, the CD4+ T cells
primed with CD14+ DCs purified from dermis (Figure 3B) or
from DC cultures (Figure 3C) secreted high amounts of
CXCL13, a chemokine that promotes follicular homing of T and
B cells. Thus, dermal CD14+ DCs, but not LCs or dermal
CD1a+ DCs, induce the differentiation of naive CD4+ T cells
into T cells that can induce naive B cells to switch isotype and dif-
ferentiate into cells that secrete large amounts of Igs.
LCs Efficiently Prime Allogeneic Naive CD8+ T Cells
The capacity of the different mDC subsets to activate allogeneic
naive CD8+ T cells (CCR7+CD45RA+CD45RO) was assessed
with [3H]-labeled thymidine and CFSE dilution (Figure 4). Indeed,
LCs were powerful stimulators of naive CD8+ T cell proliferation,
whereas dermal CD14+ DCs were weak stimulators, and dermal
CD1a+ DCs showed intermediate activity (Figures 4A and 4C),
although markedly lower compared to that of LCs. In vitro-gen-
erated LCs were also inducing the proliferation of alloreactive
CD8+ T cells more efficiently than CD14+ DCs did (Figure 4B
and Figure S6). Thus, LCs are powerful inducers of naive
CD8+ T cell proliferation.
LCs Preferentially Select and Expand
Antigen-Specific CTLs
To assess the capacity ofmDC subsets to prime antigen-specific
CD8+ T cell responses, we analyzed the priming of CD8+ T cells
specific for the melanoma differentiation antigen MART-1. The
Figure 4. LCs AreMore Efficient thanCD14+
DCs at Priming Allogeneic Naive CD8+ T
Cells
(A) Proliferation of allogeneic naive CD8+ T cells
primed with sorted skin LCs, dermal CD1a+ DCs,
or dermal CD14+ DCs was measured after 5
days by [H3]-thymidine incorporation. The graph
shows means ± SD, n = 3. Data are representative
of four independent experiments.
(B) Proliferation of allogeneic naive CD8+ T cells
primed with sorted in vitro-generated LCs or
CD14+ DCs was measured after 5 days by
[H3]-thymidine incorporation. The graph shows
mean ± SD, n = 3. Data are representative of four
independent experiments.
(C) Allogeneic naive CD8+ T cells were labeled with
CFSE (0.5 mM) and cultured for 6 days with sorted
skin LCs, dermal CD1a+ DCs, or dermal CD14+
DCs. Proliferation was determined by the dilution
of CFSE dye as analyzed by flow cytometry. Histo-
grams show the percentage of proliferating
(CFSEneg) CD3+CD8+ T cells. Data are representa-
tive of three independent experiments.
purified mDC subsets were incubated
with an HLA-A201-restricted MART-1
decamer peptide and then cultured with
purified naive CD8+ T cells for 9 days,
with soluble CD40L to ensure DC activa-
tion. LCs were able to induce considerable expansion of
MART-1-specific CD8+ T cells, as illustrated by the binding of
MART-1-HLA-A201 tetramers tocultured lymphocytes (Figure5A
and Figure S7A). CD14+ DCs were far less efficient at inducing
priming and expansion of MART-1-specific naive CD8+ T cells
(Figure 5A and Figure S7A, p < 0.0001, paired Student’s t test).
The lower efficiency of CD14+DCswas not due to T cell death re-
sulting from an overly vigorous response (data not shown and
Figure S6). LCs were alsomore potent than CD14+ DCs at induc-
ing the expansion of naive CD8+ T cells specific for another
melanoma-associated antigen, gp100, when pulsed as an HLA-
A201-binding nonamer peptide (Figures S7B and S7C). CD8+
T cells primed with MART-1-peptide-loaded LCs and CD14+
DCs were able to kill HLA-A201+ T2 cells loaded with MART-1
peptide at a high effector-to-target (E:T) ratio (Figure 5B, left
panel). However, LC-activated CD8+ T cells were always more
efficient than CD14+ DC-induced CD8+ T cells, as demonstrated
by their higher cytotoxic function at a low E:T ratio (Figure 5B,
right panel). Importantly, CD8+ cytotoxic T cells activated by
LCs were able to kill HLA-A201+ tumor targets such as ME526
in the absence of added peptide antigen (Figure 5C). In contrast,
CD8+ T cells generated with CD14+ DCs were unable to do so.
Taken together, these data indicate that LCs are more efficient
than CD14+ DCs at priming naive CD8+ T cells to become potent
cytotoxic effector cells able to respond functionally to naturally
presented amounts of TCR ligand.
LCs Induce High-Avidity CTLs
The superior cytotoxic effector properties of LC-primed CD8+
T cells as compared to CD14+ DC-primed CD8+ T cells might
be due in part to the selection of high-avidity T cells. Indeed,502 Immunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc.
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specific CD8+ T cells revealed that LC-primed CD8+ T cells
boundmore tetramers than CD14+ DC-primed CD8+ T cells (Fig-
ures 5A and 5D). The two CD8+ T cell populations showed the
same fluorescence after staining with anti-CD3 Ab, indicating
that the difference in tetramer staining was not merely due to
higher amounts of TCR expression on the LC-induced T cells
(data not shown). Indeed, LC-primed CD8+ T cells released
bound tetramers at a slower pace than did CD14+ DC-primed
CD8+ T cells (Figure 5E) (Molldrem et al., 2003). This indicates
that the LC-primed antigen-specific CD8+ T cells express
TCRs with a higher avidity for the peptide-MHC (pMHC) com-
plexes in comparison to CD14+ DC-primed antigen-specific
CD8+ T cells.
The limited CD8+ T cell priming ability of CD14+ DCs could be
due to low amounts of pMHC complexes presented on their cell
surfaces after incubation with the MART-1 peptide. However,
staining with monoclonal antibodies that specifically bind to
MART-1-HLA-A201 pMHC complexes (Noy et al., 2005) re-
vealed that after peptide loading, CD14+ DCs presented consid-
erably higher amounts of specific pMHC complexes than LCs
(Figure 5F, upper panel). The higher expression of pMHC com-
plexes by CD14+ DCs cannot be simply explained by higher
overall expression of MHC class I molecules on CD14+ DCs as
compared to LCs because both subsets displayed comparable
expression of surface MHC class I molecules (data not shown).
Similarly, CD14+ DCs loaded with a HLA-A201-restricted
gp100 peptide display higher amounts of pMHC complexes on
their surface (Figure 5F, lower panel). To determine whether
the higher amounts of pMHC complexes on CD14+ DCs had
a negative effect on the growth of specific CD8+ T cells, we
loaded CD14+ DCs with lower peptide concentrations (0.3 mM)
to approximate the amount of pMHC found on LCs. This did
not result in the generation of higher amounts of MART-1-spe-
cific CD8+ T cells with higher avidity (data not shown). Thus,
independent of the amount of TCR ligand, LCs display a prefer-
ential ability to expand high-avidity antigen-specific naive CD8+
T cells.
CD14+ DCs Induce Naive CD8+ T Cells to Express
Low Amounts of Granzymes
The low killing properties of CD8+ T cells expanded with CD14+
DCsmight be explained by an incompletematuration of the naive
CD8+ T cells into cytotoxic effectors. Indeed CD8+ T cells primed
with skin-derived LCs were found to express high amounts of
effector molecules granzyme A, granzyme B, and perforin (Fig-
ure 5G, upper row). In contrast, CD8+ naive T cells primed with
dermal CD14+ DCs (Figure 5G, lower row) expressed little gran-
zymeA andB and little perforin, thereby providing an explanation
for their limited killing properties. Dermal CD1a+DCs induced na-
ive CD8+ T cells to express higher amounts of effector molecules
when compared to CD14+ DCs, but they were less efficient in
comparison to LCs (Figure 5G, middle row). A similar phenotype
was seenwith in vitro-generated DCs, in that CD8+ T cells primed
by LCs expressed higher amounts of effector molecules com-
pared to CD14+ DCs (Figure S7D). Thus, LCs efficiently induce
the generation of cytotoxic T cells expressing high amounts of
cytotoxic proteins, whereas CD14+ DCs generate T cells with
low cytotoxic effector molecules.ILCs Efficiently Crosspresent Antigens to CD8+ T Cells
We examined the capacity of each DC subset to present external
unprocessed protein antigens to CD8+ T cells (crosspresenta-
tion). In vitro-cultured LCs and CD14+ DCs were incubated
with a recombinant influenza-virus matrix protein (Flu-MP) and
cultured with autologous CD8+ T cells and soluble CD40L. Ex-
pansion of HLA-A201-restricted Flu-MP(58–66)-specific CD8+
T cells was analyzed after 7–9 days. LCs efficiently induced pro-
liferation of Flu-MP(58–66)-specific CD8+ T cells (Figure 6A and
Figure S8A). By contrast, CD14+ DCs barely induced Flu-
MP(58–66)-specific CD8+ T cell population, even after the matu-
ration with LPS (data not shown). To assess crosspriming, we
incubated in vitro-cultured LCs and CD14+ DCs with a 15-mer
peptide (MART-1[21–35] YTTAEEAAGIGILTV) containing the
HLA-A201-restricted MART-1 decamer epitope (MART-1[26–
35] EAAGIGILTV) and cultured them for 9 days with autologous
naive CD8+ T cells and soluble CD40L. In vitro LCs were more
potent than CD14+ DCs at crosspriming MART-1(26–35)-spe-
cific CD8+ T cells, a highly reproducible finding (Figure 6B and
Figure S8B). Thus, LCs are more potent than CD14+ DCs at
crosspresenting soluble antigens.
Both CD14+ DCs and LCs Are Able to Activate
Memory T Cells
The poor capacity of CD14+DCs loadedwith Flu-MP to stimulate
Flu-MP-specific CD8+ T cells might be due to their limited ability
to stimulate memory T cells when compared to LCs (Belz et al.,
2007). Thus, we investigated whether CD14+ DCs are able to
stimulate memory Flu-MP(58–66)-specific CD8+ T cells when
loadedwith the immunodominant Flu-MP(58–66) peptide. As ob-
served earlier with the MART-1 and gp100 peptides (Figure 5F),
CD14+ DCs displayed more Flu-MP-HLA-A201 complexes than
did LCs (Figure 7A). CD14+ DCs and LCs loaded with the Flu-MP
peptide were equally potent at inducing the proliferation of Flu-
MP-specific CD8+ T cells (Figures 7B and 7C). Thus, both LCs
and CD14+ DCs are equally capable of presenting MHC class
I-restricted peptides and induce comparable expansion of
memory CD8+ T cells.
Because CD14+ DCs had not efficiently crosspresented the
Flu-MP protein to CD8+ T cells, we analyzed whether CD14+
DCs loaded with a soluble protein antigen can stimulate anti-
gen-specific memory CD4+ T cells. To this end, both DC subsets
were incubated overnight with tetanus toxin (TT) and then cul-
tured for 7 days with autologous CD4+ T cells. To detect TT-spe-
cific CD4+ T cells, activated CD4+ T cells were restimulated with
TT-loaded CD34-HPC-derived DCs for 6 hr in the presence of
monensin. CD14+ DCs loaded with TT were able to stimulate
TT-specific IL-4- and IFN-gproducing memory CD4+ T cells
even more efficiently than LCs (Figure 7D and Figure S9). Thus,
CD14+ DCs appear to be more efficient than LCs at processing
and presenting soluble proteins in the MHC class II-restricted
pathway.
DISCUSSION
The biological raison d’eˆtre for separate mDC subsets in skin,
which includes at least two dermal DC subsets, and the epider-
mal Langerhans cells has remained a puzzle until now. Our pres-
ent detailed analysis, which builds upon other earlier studiesmmunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 503
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et al., 1993; Zaba et al., 2007), reveals human skin DCs’ different
immunological functions.
One of the major findings of the present study is the demon-
stration that CD14+ DCs display a unique ability to induce the
generation of Tfh cells able to induce naive B cells to switch
isotype and produce large amounts of Igs. Indeed, the CD14+
DC-polarized T cells secrete the cytokine CXCL13, a feature
unique to the CD4+ T cell population isolated from tonsil germinal
centers. This newly identified property of CD14+ DCs, together
with our earlier demonstration of the capacity of CD14+ DCs
from cultures of CD34-DCs to induce naive B cells to secrete
IgM (Caux et al., 1997), indicates that CD14+ DCs specialize in
the control of mature B cell differentiation. This function of hu-
man DCs might also apply to mouse dermal DCs, which migrate
into the outer paracortex, just beneath the B cell follicles,
whereas LCs migrate into the T cell-rich inner paracortex (Kis-
senpfennig et al., 2005). Although able to induce naive CD4+
T cells to potently help B cells, CD14+ DCs, unlike LCs, do not
induce CD4+ T cells to secrete typical Th2 cell cytokines.
When considering naive CD8+ T cells, dermal CD14+ DCs
showed a very poor ability to induce their differentiation into po-
tent CTL effectors. This is not due to the inability to generate pep-
tide-MHC class I complexes, but rather the inability to induce the
expression of the cytotoxic effector molecules (granzymes A and
B and perforin) on the differentiating T cells. The limited ability of
CD14+ DCs to crosspresent proteins such as influenza matrix
protein is not due to a lower ability to process proteins. Rather,
as recently documented with mouse lymphoid-organ-resident
DC subsets (Dudziak et al., 2007), it represents a functional spe-
cialization in that the CD14+ DCs are more potent at processing
MHC class II-restricted peptides from tetanus toxoid.
The complexity of the dermal antigen-presenting cells (APCs),
which was identified in studies from the 1990s (Nestle et al.,
1998; Nestle et al., 1993), was recently reanalyzed (Zaba et al.,
2007), demonstrating the presence of CD11c+ CD1c(BDCA-1)+
dermal DCs and CD11c CD163+FXIIIa+ macrophages in der-
mis. The dermal macrophages are thus a further component inImthe dermal immune system. The immediate question arises as
to whether the dermal CD14+ DCs described in this study are
equivalent to the dermal CD11c CD163+FXIIIa+ macrophages.
A comprehensive analysis of the DC subsets that migrated out
of the dermis showed that both CD1a+ and CD14+ DCs express
CD11c. Thus, our CD14+ DCs, which crawl out of the dermis, are
distinct from the CD11cCD14+macrophages, which stay within
the dermis. Indeed, our preliminary studies with collagenase-in-
duceddigestion of dermis, as usedbyZaba et al., yields a hetero-
geneous population of CD14+ cells that include both DCs and
macrophages and will necessitate a detailed immunological
analysis of the various components. Our current view is that
dermal CD163+FXIIIa+ cells include both nonmigrating
CD11cCD14+ macrophages and CD11c+CD14+ migratory
DCs; the latter is indeed able to prime naive T cells into Tfh cells.
It is possible that these macrophages and CD14+ DCs cells
might transform into each other, as was shown earlier with
monocyte-derived DCs and macrophages in response to a bal-
ance of IL-6 and TNF (Chomarat et al., 2003).
Thus, our current data, together with our previous observation
that CD14+ DCs can induce B cell priming (Caux et al., 1997),
suggest that CD14+ DCs have a special capacity to both indi-
rectly (through T cell polarization) and directly affect B cell differ-
entiation toward antibody secretion.
Our detailed studies on naive CD8+ T cell priming with class I
binding peptides, as well as crosspriming with proteins and poly-
peptides that require processing, indicate that LCs are strong
inducers of the differentiation of naive CD8+ T cells into potent
cytotoxic effectors. Indeed, naive CD8+ T cells primed by LCs
acquire high amounts of granzyme A and B, as well as perforin.
Studies performed with CD34-HPC-derived DCs loaded with
killed tumor cells (Cao et al., 2007; Ratzinger et al., 2004) also
indicated that LCs and CD14+ DCs were able to induce some
priming of CD8+ T cells, provided several culture cycles were
performed. Under these conditions and in variance from our cur-
rent findings, LCs were not markedly more potent than CD14+
DCs, a finding that might come from a differential processing
of dead tumor cells and proteins. Our data therefore extendFigure 5. LCs Are More Efficient than CD14+ DCs at Priming Antigen-Specific High-Avidity Effector CD8+ T Cells
(A) In vitro-generated LCs or CD14+ DCs from an HLA-A201+ donor were loaded with an HLA-A201-restricted MART-1(26–35) peptide (3 mM) and cultured with
naive CD8+ T cells for 9 days. The expansion of antigen-specific CD8+ T cells was assessed by flow cytometry withMART-1(26–35)-HLA-A201 tetramer. Data are
representative of 15 independent experiments.
(B) The cytotoxic activity of MART-1(26–35)-specific CD8+ T cells primed by in vitro-generated LCs and CD14+ DCs was assessed in a standard 51Cr release
assay against T2 cells loaded with 108 M MART-1(26–35) peptide at high Effector to Target (E:T) ratio (30:1, left panel) and a lower E:T ratio (4:1, right panel).
Graph shows data of four independent experiments. Results were obtained by paired Student’s t test.
(C) The cytotoxic activity of MART-1(26–35)-specific CD8+ T cells primed by in vitro-generated LCs and CD14+ DCs was assessed in a standard 51Cr release
assay against an HLA A201+ melanoma cell line MEL526 expressing MART-1 at high E:T ratio (30:1). Graph shows data of four independent experiments. Results
were obtained by paired Student’s t test.
(D) MART-1(26–35)-HLA-A201 tetramer fluorescence intensity of CD8+ T cells primed by MART-1(26–35)-peptide-loaded LCs or CD14+ DCs. Graph shows data
of 15 independent experiments. Results were obtained by paired Student’s t test.
(E) Dissociation rate of MART-1(26–35)-HLA-A201 tetramers from CD8+ T cells primed by LCs or CD14+ DCs. CD8+ T cells primed for 9 days by MART-1(26–35)-
loadedmDC subsets were stainedwithMART-1(26–35)-HLA-A201 tetramer, and thenwe added an excess of unlabeled anti-HLA-A201mAb to prevent rebinding
of the tetramer after dissociation. The intensity of tetramer fluorescence was analyzed at various time points by flow cytometry. Data are shown as the natural
logarithm of the percentage of maximum fluorescence ± SD, n = 3 (corresponding to mean fluorescence at t0), plotted against time.
(F) In vitro-generated mDC subsets from an HLA-A201 donor were loaded with either MART-1(26–35) or gp100(209–217) peptide and stained with tetramerized
mAbs that were endowed with a TCR-like specificity and that recognized the corresponding MART-1(26–35)-HLA-A201 (upper panel) and gp100(209–217)-HLA-
A201 peptide complexes (lower panel). Histograms show staining of the gated distinct mDC subset. Data are representative of four independent experiments.
(G) Allogeneic naive CD8+ T cells primed for 7 days by each skin mDC subset (LCs [upper row], dermal CD1a+ DCs or CD14+ DCs [middle and lower rows,
respectively]) were stained and analyzed by flow cytometry for the expression of the effector molecules granzyme A, granzyme B, and perforin. Data are
representative of four independent experiments.munity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 505
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ing IFN-g-secreting CD8+ T cells than monocyte-derived DCs
(Ratzinger et al., 2004).
Although LCs are less efficient in MHC class II peptide presen-
tation than CD14+ DCs, as shown by the activation of tetanus-
toxoid-specific memory T cells, they were able to polarize naive
CD4+ T cells into cells secreting Th2 cell-type cytokines. Indeed,
our findings might explain the preferential skewing toward Th2
cell responses that was observed in T cells from mice receiving
antigen in the epidermis (rich in LCs) through antigen-loaded
gold particles delivered with a gene gun (Alvarez et al., 2005).
Both LCs and CD14+DCs are capable of inducing IFN-g-secret-
ing CD4+ T cells. However, further studies are necessary to
establish whether the IFN-g-secreting CD4+ T cells generated
in response to CD14+ DCs are biologically equivalent to those
made in the presence of LCs. In contrast, LCs were not capable
of inducing Tfh development, nor are they capable of inducing
naive B cells to secrete IgM (Caux et al., 1997). Indeed, the local-
ization of LCs to the inner paracortex is consistent with their
ability to prime CD8+ T cells and CD4+ T cells.
For many years, LCs have been viewed as a paradigmatic
population in DC biology, whereby DCs survey and sense path-
ogens, become activated, and migrate to the draining lymph
Figure 6. LCsAreMore Efficient thanCD14+DCs atCrosspresenting
Antigens to CD8+ T Cells
(A) To assess crosspresentation, in vitro-generated LCs or CD14+ DCs from an
HLA-A201 donor, were incubated with soluble Flu-MP and autologous purified
CD8+ T cells. After 7–9 days, the expansion of Flu-MP(58–66)-specific CD8+
T cells was assessed by flow cytometry with Flu-MP(58–66)-HLA-A201 tetra-
mer. Data are representative of 12 independent experiments.
(B) To assess crosspriming, in vitro-generated LCs or CD14+ DCs from an
HLA-A201 donor were incubated with a 15-mer MART-1 peptide (MART-
1[21–35]) and autologous naive CD8+ T cells. After 9 days, the expansion of
MART-1(26–35)-specific CD8+ T cells was assessed by flow cytometry with
MART-1(26–35)-HLA-A201 tetramer. Data are representative of ten indepen-
dent experiments.506 Immunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc.node, where they present antigens to lymphocytes, resulting in
pathogen-specific immune responses. Recent studies in mice,
however, have challenged this concept. Studies with herpes
simplex viruses (HSV) suggested that LCs had no role in the de-
velopment of an immune response against the virus (Allan et al.,
2003; Zhao et al., 2003). Rather, dermal DCs appeared to trans-
port the viral antigens into the draining lymph nodes and deliver
them to the resident DCs (Allan et al., 2006). Genetic depletion of
LCs in mice resulted in either normal (Kissenpfennig et al., 2005),
increased (Kaplan et al., 2005), or decreased (Bennett et al.,
2005) hypersensitivity reactions. Our findings are, however, in
line with studies performed in mice that involved peptide-loaded
epidermal DCs injected subcutaneously (Celluzzi and Falo, 1997)
or lentiviral vectors delivered to LCs by genetic immunization (He
et al., 2006). Furthermore, consistent with our data, another
recent mouse study shows that LCs crosspresent antigens to
CD8+ T cells in vivo (Stoitzner et al., 2006). Thus, although stud-
ies in mice have not yet settled the matter of the role of LCs, our
data indicate that human LCs preferentially activate cell-medi-
ated immunity.
Our study shows that dermal CD1a+ DCs represent an impor-
tant population of DCs that are present in the upper layer of the
dermis. They are most likely the dermal BDCA1+ cells described
by Zaba et al. because they express CD1c, the antigen recog-
nized by theBDCA-1 antibody. This population is a potent inducer
of the proliferation of allogeneic CD4+ T cells (this study and Zaba
et al., 2007) and CD8+ T cells, although less efficient than LCs. In-
deed, their phenotype is closer to that of LCs than that of CD14+
DCs. A major exception is the lack of Langerin and E-cadherin,
which are characteristic of LCs. Indeed, Langerin expression
could be detected solely on LCs in the epidermis in situ. Similar
to LCs, dermal CD1a+ DCs essentially produce IL-15 and little
of the proinflammatory molecules expressed by dermal CD14+
DCs, with the possible exception of IL-8. They are, however,
less potent than LCs in inducing the polarization of CD4+ T cells
into Th2 cells and that of naive CD8+ T cells into highly potent
granzyme A and B and perforin-positive CTLs. They might repre-
sent the precursors of LCs, and theymight also correspond to the
recently identified mouse Langerin+ dermal DCs that are capable
of participating in skin immune response (Bursch et al., 2007;
Ginhoux et al., 2007; Poulin et al., 2007).
As observed earlier with CD34+-derived in vitro-generated
DCs (de Saint-Vis et al., 1998), skin LCs andCD14+ DCs produce
a dramatically distinct panel of cytokines. In particular, CD14+
DCs spontaneously and in response to CD40 ligation produce
IL-10 and TGFb, as well as multiple proinflammatory cytokines.
In contrast, LCs produce only a limited set of cytokines (IL-8
and most prominently IL-15). Our attempts to identify the molec-
ular mechanisms endowing CD14+ DCs and LCs with their spe-
cialized functions have thus far been only partly conclusive. As in
an earlier study (Dudziak et al., 2007), we found that LCs express
more genes related to the MHC class I pathway, and CD14+ DCs
express more genes related to the MHC class II pathway (data
not shown), and such a finding may explain the superior ability
of LCs to crosspresent peptides on class I molecules to CD8+
T cells. Looking at the cell surface, LCs express more 4-1BB-
L, an activator of CD8+ T cells (Watts, 2005), but anti-4-1BB-L
blocked T cell priming by both subsets (data not shown). Further-
more, LCs, but not CD14+ DCs, express IL-15, which is known to
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Different DCs Prime Cellular and Humoral ImmunityFigure 7. Both CD14+ DCs and LCs Efficiently Activate Memory T Cells
(A) In vitro-generated mDC subsets from an HLA-A201 donor were loaded with Flu-MP(58–66) peptide and stained with a tetramerized-mAbs that were endowed
with a TCR-like specificity and that recognized the corresponding Flu-MP(58–66)-HLA-A201 peptide complex. Histograms show staining of the gated distinct
mDC subsets. Data are representative of four independent experiments.
(B) In vitro-generated LCs or CD14+ DCs from an HLA-A201+ donor were loaded with Flu-MP(58–66) peptide and cultured for 9 days with purified CD8+ T cells.
The frequency of Flu-MP(58–66)-specific CD8+ T cells was analyzed by flow cytometry with Flu-MP(58–66)-HLA-A201 tetramer. Data are representative of
15 independent experiments.
(C) Kinetics of Flu-MP(58–66)-specific CD8+ T cell expansion in response to stimulation with peptide-loaded LCs or CD14+ DCs. The number of antigen-specific
CD8+ T cells was calculated, on indicated days, on the basis of the total number of cells in the culture and the frequency of Flu-MP(58–66)-HLA-A201 tetramer-
positive cells. Data are representative of three independent experiments.
(D) Intracytoplasmic production of IFN-g and IL-4 by TT-specific CD4+ T cells. Cells were stimulated for 7 days with TT-loaded or -unloaded autologous
in vitro-generated mDC subsets. The production of IFN-g and IL-4 was assessed by flow cytometry in response to a restimulation with TT-loaded CD34-derived
DCs. Data are representative of four independent experiments.enhance CD8+ T cell responses (Oh et al., 2004). However, none
of the mAbs we have tried were convincingly able to inhibit LC-
induced CD8+ T cell priming, whereas they were able to inhibit
the proliferation of T cells induced by exogenous IL-15 (data
not shown). We could, however, enhance CD14+ DC-mediated
priming of CD8+ T cells by adding to the culture external IL-15,
which could be blocked by anti-IL15 (not shown). CD14+ DCs,
on the other hand, produce IL-10 and TGF-b and polarize naive
CD8+ T cells into poor effector cells expressing little granzyme A
and B and perforin. Addition of IL-10 can induce LCs to polarize
CD8+ T cells into cells with low granzyme A and B and perforin.IIndeed, the earlier demonstration that addition of IL-10 of cocul-
tures of monocyte-derived DCs allows the generation of CD4+
Treg cells is a step in this direction (Roncarolo et al., 2006; Stein-
brink et al., 1999). However, blocking IL-10 appears to be insuf-
ficient for CD14+ DCs to induce potent effector CD8+ T cells.
The capacity of LCs and CD14+ DCs to preferentially prime
cellular immunity and humoral immunity, respectively, has im-
portant implications, most particularly in the context of novel hu-
man vaccines. The effective vaccines developed against a vari-
ety of infectious agents, including polio, measles, and hepatitis
B, certainly represent major achievements inmedicine. Yet thesemmunity 29, 497–510, September 19, 2008 ª2008 Elsevier Inc. 507
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capacity arises largely from their induction of humoral immune
responses (Pulendran and Ahmed, 2006). Given both the
methods by which these vaccines are delivered and the data
presented here, it is likely that these vaccines principally activate
and deliver antigen to CD14+ DCs and possibly CD1a+ DCs, but
not LCs. In any case, our current study argues that targeting LCs
will be important for the design of cutaneous vaccines that aim at
eliciting strong cellular immunity. Such vaccines might be partic-
ularly useful at preventing, and perhaps even treating, chronic
diseases involving viral (HIV, hepatitis C virus), bacterial (myco-
bacteria), and parasitic (malaria) diseases, as well as cancer
(Letvin, 2007). The most efficient vaccines might actually be
those that will target both CD14+ DCs and LCs, thereby allowing
the maximal stimulation of both humoral and cellular immune
responses. In this regard, it is intriguing to consider that one of
the most effective vaccines, smallpox vaccine (Frey et al.,
2002; Pulendran and Ahmed, 2006), acts through a combination
of strong cellular and humoral immunity and requires scarifica-
tion of the skin, a procedure that injures both epidermis and
dermis and that is likely to mobilize and activate LCs as well as
dermal DCs.
EXPERIMENTAL PROCEDURES
Isolation of mDC Subsets
LCs, dermal CD1a+ DCs, and CD14+ DCs were purified from normal human
skin. Subjects were recruited at the Baylor University Medical Center of Dallas.
The study was approved by the Institutional Review Board of Baylor Research
Institute, and informed consent was obtained from all patients. Specimens
were incubated with the bacterial protease dispase type 2 for 18 hr at 4C
and then for 2 hr at 37C. Epidermal and dermal sheets were separated and
placed in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). After
2 days, the cells that migrated into the medium were enriched with a Ficoll-
diatrizoate gradient. DCs were purified by cell sorting after staining with
anti-CD1a FITC and anti-CD14 APC mAbs. LCs, dermal CD1a+ DCs, and der-
mal CD14+ DCs represent 58%, 30%, and 12% of the total skin DCs, respec-
tively. Where indicated, sorted DCs were stimulated with either soluble CD40L
(100 ng/ml, R&D) or LPS (50 ng/ml, Sigma) for 24 hr. Cytokine production was
measured in culture supernatants after 24 hr with a multiplex bead assay
(Luminex). Immunostaining and microscopic analysis of human skin sections,
as well as Microarray gene analysis, are detailed in the Supplemental Data.
Generation of mDC Subsets
DCs were generated in vitro from CD34-HPCs isolated from the blood of
healthy volunteers. HPCs were cultured at 5 3 105 cells/ml in Yssel’s medium
(Irvine Scientific) supplemented with 5% autologous serum, 50 mM b-mercap-
toethanol, 1% L-glutamine, 1% penicillin/streptomycin, GM-CSF (50 ng/ml;
Berlex), Flt3L (100 ng/ml; R&D), and TNFa (10 ng/ml; R&D) for 9 days. Media
and cytokines were refreshed at day 5 of culture. Subsets of DCs,
CD1a+CD14LCs and CD1aCD14+ DCs were then sorted, yielding a purity
of 95%–99%. Intracellular IL-15 was analyzed in the cell lysate of purified
sorted DC subsets by a multiplex bead assay (Luminex).
CD4+ T Cell Experiments
Naive CD4+ T cells (CCR7+CD45RA+ CD4+) were sorted from PBMCs after
CD8-, CD56-, CD16-, and CD19-magnetic cell depletion (Miltenyi). For as-
sessment of DC allostimulatory capacity, naive CD4+ T cells (5 3 104/well)
were cultured in 96-well plates in Yssel’s medium supplemented with 10%
heat-inactivated pooled AB human serum (Yssel’s complete medium), to
which allogeneic mDC subsets were added at graded cell numbers. After
5 days, cells were pulsed for 18 hr with 1 mCi [3H]-thymidine and then har-
vested. Alternatively, cell proliferation was assessed by a CFSE dilution.508 Immunity 29, 497–510, September 19, 2008 ª2008 Elsevier IncFor cytokine production, naiveCD4+ T cells (53 104 perwell) were stimulated
with allogeneic DCs (53 103 in vitro DCs per well; 2.53 103 with skin DCs per
well) in 96-well plates for 7 days. Proliferating CD4+ T cells were sorted as
FSChighCD11c and restimulated overnight with anti-CD3 and anti-CD28
coatedmicrobeads.Cytokinesweremeasuredbyamultiplexbeadassay (Lumi-
nex), andCXCL13wasmeasuredbyELISA (R&D). For intracytoplasmiccytokine
analysis, primedCD4+ T cells were restimulatedwith 50 ng/ml PMA and 1 mg/ml
ionomycin (Sigma) for 6hr in thepresenceofmonensin.Fixedandpermeabilized
cellswere stainedwithanti-IFN-gFITCandanti-IL-4PEmAbs (BDBiosciences).
For measurement of functions involving B cell priming differentiation, sorted
FSChighCD11cCD4+ T cells were cocultured with autologous naive B cells. B
cells were preincubated with anti-IgM mAb (BD biosciences) and CpG2006
(2.5 mg/ml; InVivoGen) for 2 hr. T cells (indicated numbers/well) and B cells
(23 104 cells/well) were cocultured in 96-well plates for 14 days. Igs in super-
natants were measured by ELISA.
For recall responses, total CD4+ T cells (13 105 cells/well) were stimulated in
96-well plates with autologous in vitro mDC subsets (13 104 cells/well) prein-
cubated with TT (10 LfU/ml). Cells were harvested at day 7 and restimulated
with TT-loaded total CD34-DCs for 5 hr in the presence of monensin. Intracy-
toplasmic cytokine secretion was analyzed by flow cytometry.
CD8+ T Cell Experiments
Naive CD8+ T cells were sorted as CD45RA+CCR7+HLA-DRCD8+ cells. Allo-
geneic primed CD8+ T cells were characterized for the expression of cytotoxic
effector molecules, granzyme A (BD PharMingen), granzyme B (eBioscience),
and perforin (Fitzgerald) after 7 days of coculture with mDC subsets. For pri-
mary response, naive CD8+ T cells (1 x106 cells/well) were stimulated with au-
tologous LCs or CD14+ DCs (53 104 cells/well) that were preincubated for 3 hr
with the HLA-A201-restricted MART-1 (MART-1[26–35], ELAGIGILTV), gp100
(gp100[209–217], IMDQVPFSV), or a control peptide (3mM).Cellswere cultured
for 9 days in 24-well plateswith 10U/ml IL-7 (R&D) and 100 ng/mlCD40L (R&D).
IL-2 was added at 10 U/ml at day 3. For crosspresentation experiments, each
mDC subset was incubated with 15 aa MART-1(21–35) peptide (YTTAEEAAGI
GILTV) or Flu-MPprotein andwith purifiedCD8+ T cells with 10U/ml IL-7 (R&D).
100ng/mlCD40L (R&D)wasaddedafter 24hr, and IL-2wasaddedat 10U/ml at
day 3. Expansion of peptide-specific CD8+ T cells was determined by counting
the number of cells binding peptide-HLA-A201 tetramers (Beckman Coulter).
Cytolytic assays were performed in a standard 51Cr release assay with pep-
tide-loaded T2 cells and an HLA-A201+ melanoma cell line, ME526, as targets,
after two rounds of T cell stimulation with the same DC subsets.
Antigen-specific TCR avidity was analyzed by measuring the decay of
peptide-HLA-A201 tetramer binding. CD8+ T cells primed by MART-1(26–
35)-loaded mDC subsets were stained with MART-1-HLA-A201 tetramer; an
excess of unlabeled anti-HLA-A201 mAb (BB7.2; BD Biosciences) was then
added to prevent rebinding dissociated tetramer. The intensity of tetramer
fluorescence, analyzed by flow cytometry at various time points, is plotted in
the natural logarithm scale of the initial fluorescence (Molldrem et al., 2003).
For quantitating pMHC-complexes on DCs, DCs were loaded with HLA-
A201-restricted MART-1(26–35), gp100(209–217), or Flu-MP(58–66) peptides
for 3 hr and stained with PE-conjugated tetramerized mAbs that recognize
each peptide-HLA-A201 complex (Clones CAG10, H9, and M1D12, respec-
tively) (Noy et al., 2005). For recall responses, total CD8+ T cells (1 3 105 cells
per well) were stimulated in 96-well plates with autologous mDC subsets (5 3
103cells per well) loaded with HLA-A201-restricted Flu-MP(58–66) peptide
(GILGFVFTL). The frequency of Flu-MP-specific CD8+ T cells was determined
with Flu-MP-HLA-A201 tetramer.
For the production of Flu-MP, the ORF of gij60458j Flu M1 protein (Influenza
A virus [A/WSN/1933(H1N1)]) with a V15I substitution was inserted into pET-
28b (+) (Novagen). The protein was expressed in T7 Express cells (NEB) and
purified by flow through Q Sepharose and then sequential Ni2+ chelating and
S Sepharose chromatographies.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and nine
figures and can be found with this article online at http://www.immunity.
com/cgi/content/full/29/3/497/DC1/..
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